Therapeutic composition and method combining multiplex immunotherapy with cancer vaccine for the treatment of cancer
This invention relates to a therapeutic composition comprising i) at least two immune checkpoint inhibitors, ii) at least one drug selected from a cytokine a cytotoxic or cytostatic chemotherapeutic drug, and combinations thereof, and iii) a cancer vaccine prepared from tumor or cancer cells, or derivatives thereof, that have been prepared through an ex vivo treatment that creates necrotic and/or necroptotic cancer cells while minimizing destruction of cancer antigens. This invention also relates to a method of treating a tumor or a cancer in a patient comprising administering to a patient in need thereof the therapeutic composition in an amount effective to treat the tumor or cancer.
1. A method of treating a tumor or a cancer in a subject in need consisting of:
intradermally administering to the subject a therapeutic composition consisting of:
i) two immune checkpoint inhibitors comprising a CTLA-4 inhibitor, and a PD-1 inhibitor or PD-L1 inhibitor,
ii) cyclophosphamide, and
iii) a cancer vaccine prepared from cancer cell lysates that have been prepared through an ex vivo treatment consisting of irradiation, cryofreezing, and suspension in a low-dose solution of cyclophosphamide, that creates necroptotic cancer cells while minimizing destruction of cancer antigens, in an amount effective to treat the tumor or cancer,
wherein the cancer cell lysates are prepared by one or more treatments selected from the group consisting of dissociation or dissection, fixation, centrifugation, resuspension, enrichment, and combinations thereof; and
post intradermal administration of the therapeutic composition, further administering a drug selected from a cytokine drug, a cytotoxic or cytostatic chemotherapeutic drug, and combinations thereof, to the subject daily.
2. The method of claim 1 , wherein the drug is GM-CSF or cyclophosphamide.
3. The method of claim 1 , wherein the drug is a cytokine drug administered subcutaneously or a cytotoxic or cytostatic chemotherapeutic drug administered orally.
4. The method of claim 1 , wherein the therapeutic composition is administered to the subject's skin or soft tissue using an injection device.
5. The method of claim 1 , wherein the concentration of the CTLA-4 inhibitor ranges from about 0.5 to about 10 mg/ml, and the concentration of the PD-1 or the PD-L1 inhibitor ranges from about 0.5 to about 20 mg/ml.
6. The method of claim 1 , wherein the cancer cell lysates have been fixed by formalin, ethanol, or glutaraldehyde.
7. The method of claim 1 , wherein the cryofreezing is carried out using a single probe, with total manipulating time of no more than 10 minutes.
8. The method of claim 1 , wherein the cryofreezing is carried out at a temperature from about −35 to about −100° C.
9. The method of claim 1 , wherein the cancer vaccine is autologous and the cancer cell lysates are from the subject being treated.
10. The method of claim 1 , wherein the cancer vaccine is allogenic and wherein the cancer cell lysates are from cancer cell lines.
11. A method of treating a tumor or a cancer in a subject in need consisting of:
intradermally administering to the subject a therapeutic composition consisting of:
i) two immune checkpoint inhibitors comprising a CTLA-4 inhibitor, and a PD-1 inhibitor or PD-L1 inhibitor,
ii) cyclophosphamide, and
iii) a cancer vaccine prepared from cancer cell lysates that have been prepared through an ex vivo treatment consisting of irradiation, cryofreezing, and suspension in a low-dose solution of cyclophosphamide, that creates necroptotic cancer cells while minimizing destruction of cancer antigens, in an amount effective to treat the tumor or cancer,
wherein the cancer cell lysates are prepared by one or more treatments selected from the group consisting of dissociation or dissection, fixation, centrifugation, resuspension, enrichment, and combinations thereof.
12. The method of claim 11 , wherein the therapeutic composition is administered to the subject's skin or soft tissue using an injection device.
13. The method of claim 11 , wherein the concentration of the CTLA-4 inhibitor ranges from about 0.5 to about 10 mg/ml, and the concentration of the PD-1 or the PD-L1 inhibitor ranges from about 0.5 to about 20 mg/ml.
14. The method of claim 11 , wherein the cancer cell lysates have been fixed by formalin, ethanol, or glutaraldehyde.
15. The method of claim 11 , wherein the cryofreezing is carried out using a single probe, with total manipulating time of no more than 10 minutes.
16. The method of claim 11 , wherein the cryofreezing is carried out at a temperature from about −35 to about −100° C.
17. The method of claim 11 , wherein the cancer vaccine is autologous and the cancer cell lysates are from the subject being treated.
18. The method of claim 11 , wherein the cancer vaccine is allogenic and wherein the cancer cell lysates are from cancer cell lines.